Related Experiment Videos
Endocrine therapy in pancreatic carcinoma
1Department of Surgery II, Kumamoto University School of Medicine, Kumamoto, Japan.
Oncology
|December 16, 1998
Summary
Sex hormones may impact pancreatic cancer, but its benefit from endocrine therapy is debated. Tissue plasminogen activator may guide treatment efficacy in a subgroup of patients with pancreatic carcinoma.
Area of Science:
- Oncology
- Endocrinology
- Biochemistry
Background:
- Sex hormones, particularly estrogen, may influence pancreatic carcinoma growth.
- Estrogen receptors (ER) are present in human and animal pancreatic tumors, suggesting potential for endocrine therapy.
- The efficacy of hormonal manipulation in pancreatic cancer treatment remains controversial due to a lack of predictive markers.
Purpose of the Study:
- To review the role of tissue plasminogen activator (tPA) as a prognostic marker for endocrine therapy in pancreatic carcinoma.
- To identify patient subgroups who may benefit from endocrine treatment for pancreatic cancer.
Main Methods:
- Review of research on tissue plasminogen activator (tPA) in human pancreatic carcinoma.
- Evaluation of tPA as a prognostic guide for hormonal therapy efficacy.
- Analysis of potential benefits of medroxyprogesterone acetate treatment.
Main Results:
- Tissue plasminogen activator (tPA) shows potential as a prognostic guide in pancreatic carcinoma.
- A specific patient subgroup with pancreatic cancer may respond positively to endocrine therapy.
Conclusions:
- Tissue plasminogen activator (tPA) can help evaluate hormonal therapy efficacy in pancreatic cancer.
- Selected patients with pancreatic carcinoma may benefit from endocrine therapy, particularly medroxyprogesterone acetate.